PCOS: BMI, basal androstenedione predict IVF miscarriage

  • Yang W & al.
  • Reprod Biol Endocrinol
  • 19 Nov 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A retrospective study suggests that BMI and basal levels of androstenedione are associated with risk for miscarriage in women with PCOS undergoing a gonadotropin-releasing hormone (GnRH)-antagonist protocol for in vitro fertilization (IVF).

Why this matters

  • Both factors had moderate predictive ability on the miscarriage rate.
  • The prognostic value of basal androstenedione was slightly stronger than that of BMI.

Key results

  • Patients with overweight, hyperandrogenemia (HA) status had a higher miscarriage rate (45.2% vs 14.5%; P<.05 and a lower live birth rate vs compared with patients nonoverweight non-ha status.>
  • BMI (OR, 1.097; P=.049) and basal androstenedione (OR, 1.071; P=.034) were independently associated with miscarriage rate in multivariate analysis.
  • BMI >25.335 had an area under the curve of 0.607 (P=.029), a sensitivity of 51.1%, and a specificity of 73.7% for predicting miscarriage.
  • Basal androstenedione >10.95 had an area under the curve of 0.657 (P=.001), a sensitivity of 72.3%, and a specificity of 58.4% for predicting miscarriage.

Study design

  • 583 infertile women with PCOS who underwent IVF with a standard GnRH-antagonist protocol were analyzed for effects of BMI and androstenedione on pregnancy outcomes.
  • Funding: National Natural Science Foundation of China.

Limitations

  • Retrospective study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit